Sec Form 4 Filing - MPM BIOVENTURES 2018, L.P. @ Entrada Therapeutics, Inc. - 2024-12-10

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person MPM BIOVENTURES 2018, L.P. 2. Issuer Name and Ticker or Trading Symbol Entrada Therapeutics, Inc. [ TRDA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100 3. Date of Earliest Transaction (MM/DD/YY) 12/10/2024 (Street) BOSTON, MA02116 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12/10/2024 S 22,935 ( 1 ) D $ 20.77 ( 2 ) 4,402,849 I See Footnote ( 3 ) ( 4 ) Common Stock 12/11/2024 S 21,787 ( 5 ) D $ 20.23 ( 6 ) 4,381,062 I See Footnote ( 4 ) ( 7 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other MPM BIOVENTURES 2018, L.P. C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON, MA02116 X MPM BioVentures 2018 LLC C/O MPM CAPITAL BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON, MA02116 X MPM BioVentures 2018 GP LLC C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON, MA02116 X Signatures /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018, L.P. 12/12/2024 Signature of Reporting Person Date /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC 12/12/2024 Signature of Reporting Person Date /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC 12/12/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares were sold as follows: 10,415 by MPM BioVentures 2014, L.P. ("BV 2014"), 695 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 358 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10 688 by MPM BioVentures 2018, L.P. ("BV2018"), 568 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 211 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect generalpartners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is themanager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. ( 2 )Price represents the weighted average sale price of the shares sold. The sale price ranged from $20.356 to $21.315 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regardingthe number of shares sold at each separate price within the range set forth in this Form 4. ( 3 )The shares are held as follows: 1,999,261 by BV 2014, 133,347 by BV 2014(B), 68,816 by AM BV2014, 2,051,874 by BV 2018, 109,055 by BV 2018(B) and 40,496 by AM BV2018. ( 4 )Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. ( 5 )The shares were sold as follows: 9,893 by BV 2014, 660 by BV 2014(B), 341 by AM BV2014, 10,153 by BV 2018, 540 by BV 2018(B) and 200 by AM BV2018. ( 6 )Price represents the weighted average sale price of the shares sold. The sale price ranged from $20.01 to $20.595 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regardingthe number of shares sold at each separate price within the range set forth in this Form 4. ( 7 )The shares are held as follows: 1,989,368 by BV 2014, 132,687 by BV 2014(B), 68,475 by AM BV2014, 2,041,721 by BV 2018, 108,515 by BV 2018(B) and 40,296 by AM BV2018.

Remarks: See Form 4 for MPM BioVentures 2014, L.P for additional members of this joint filing.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.